{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:40:01Z","timestamp":1758937201236,"version":"3.44.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.leukres.2013.07.029","type":"journal-article","created":{"date-parts":[[2013,9,7]],"date-time":"2013-09-07T18:01:04Z","timestamp":1378576864000},"page":"1395-1403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Striving to achieve safe, permanent treatment discontinuation in chronic myeloid leukemia"],"prefix":"10.1016","volume":"37","author":[{"given":"Michael J.","family":"Mauro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2013.07.029_bib0005","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.07.029_bib0010","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2013.07.029_bib0015","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2013.07.029_bib0020","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2013.07.029_bib0025","first-page":"1123","article-title":"Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"2","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.07.029_bib0030","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.leukres.2013.07.029_bib0035","unstructured":"Bosulif\u00ae (bosutinib) [prescribing information]. New York, NY: Pfizer Labs; 2012."},{"key":"10.1016\/j.leukres.2013.07.029_bib0040","unstructured":"Iclusig\u00ae (ponatinib) [prescribing information]. Cambridge, MA: ARIAD Pharmaceuticals, Inc.; 2012."},{"key":"10.1016\/j.leukres.2013.07.029_bib0045","unstructured":"Synribo\u00ae (omacetaxine mepesuccinate) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2012"},{"key":"10.1016\/j.leukres.2013.07.029_bib0050","first-page":"1126","article-title":"International randomized study of interferon versus STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.leukres.2013.07.029_bib0055","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.07.029_bib0060","doi-asserted-by":"crossref","first-page":"6504","DOI":"10.1200\/jco.2012.30.15_suppl.6504","article-title":"Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up","volume":"30","author":"Hochhaus","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.07.029_bib0065","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/cncr.11223","article-title":"Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis","volume":"97","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2013.07.029_bib0070","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.2002.20.1.214","article-title":"Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon-\u03b1","volume":"20","author":"Mahon","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.07.029_bib0075","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.07.029_bib0080","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia, v.4.2013."},{"key":"10.1016\/j.leukres.2013.07.029_bib0085","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.07.029_bib0090","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2013.07.029_bib0095","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1158\/1078-0432.CCR-07-0844","volume":"13","author":"Branford","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2013.07.029_bib0100","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.leukres.2013.07.029_bib0105","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER Study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.07.029_bib0110","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2009-11-255109","article-title":"In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib","volume":"116","author":"Sobrinho-Simoes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.07.029_bib0115","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1038\/sj.leu.2402730","article-title":"Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients","volume":"16","author":"Guo","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.07.029_bib0120","article-title":"A single-arm, open-label, multicenter study of complete molecular response (CMR) in patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib","volume":"30","author":"Savona","year":"2012","journal-title":"J Clin Oncol (ASCO Annual Meeting Abstracts)"},{"key":"10.1016\/j.leukres.2013.07.029_bib0125","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1093\/nar\/25.10.1999","article-title":"Nanoliter scale PCR with TaqMan detection","volume":"25","author":"Kalinina","year":"1997","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.leukres.2013.07.029_bib0130","doi-asserted-by":"crossref","first-page":"9236","DOI":"10.1073\/pnas.96.16.9236","article-title":"Digital PCR","volume":"96","author":"Vogelstein","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.leukres.2013.07.029_bib0135","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nrclinonc.2011.17","article-title":"Hematology: curing CML with imatinib \u2013 a dream come true","volume":"8","author":"Deininger","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.leukres.2013.07.029_bib0140","first-page":"7","article-title":"Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission","volume":"10","author":"Serpa","year":"2010","journal-title":"BMC Blood Disord"},{"key":"10.1016\/j.leukres.2013.07.029_bib0145","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.2009.26.7757","article-title":"Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase","volume":"28","author":"Goldman","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.07.029_bib0150","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","article-title":"Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease","volume":"118","author":"Chomel","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.07.029_bib0155","first-page":"3781","volume":"118","author":"Rousselot","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.leukres.2013.07.029_bib0160","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.leukres.2005.01.009","article-title":"Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML) Outcome of discontinuation of imatinib therapy after achieving a molecular remission","volume":"29","author":"Ali","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2013.07.029_bib0165","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","article-title":"Discontinuation of imatinib therapy after achieving a molecular response","volume":"104","author":"Cortes","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.07.029_bib0170","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.leukres.2008.11.027","article-title":"Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR\/ABL, A case report and a review of the literature","volume":"33","author":"Guastafierro","year":"2009","journal-title":"Leuk Res"},{"issue":"Suppl 1","key":"10.1016\/j.leukres.2013.07.029_bib0175","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.leukres.2003.10.017","article-title":"Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission","volume":"28","author":"Mauro","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2013.07.029_bib0180","first-page":"979","article-title":"Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation","volume":"90","author":"Merante","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2013.07.029_bib0185","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.leukres.2006.03.011","article-title":"Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon","volume":"30","author":"Breccia","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2013.07.029_bib0190","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1600-0609.2004.00257.x","article-title":"Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia","volume":"72","author":"Ghanima","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2013.07.029_bib0195","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ajh.20096","article-title":"Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases","volume":"76","author":"Higashi","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2013.07.029_bib0200","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2169\/internalmedicine.48.1687","article-title":"Successful delivery after planned discontinuation of imatinib in a patient with chronic myeloid leukemia","volume":"48","author":"Kobayashi","year":"2009","journal-title":"Intern Med"},{"key":"10.1016\/j.leukres.2013.07.029_bib0205","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1532\/IJH97.06187","article-title":"Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy","volume":"85","author":"Okabe","year":"2007","journal-title":"Int J Hematol"},{"key":"10.1016\/j.leukres.2013.07.029_bib0210","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1080\/10428190802043903","article-title":"Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha","volume":"49","author":"Verma","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2013.07.029_bib0215","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3109\/10428194.2011.649753","article-title":"Sustained complete molecular response of chronic myeloid leukemia after discontinuation of second-generation tyrosine kinase inhibitors","volume":"53","author":"Aoki","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2013.07.029_bib0220","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood-2010-04-280206","article-title":"Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response","volume":"116","author":"Kuwabara","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.07.029_bib0225","first-page":"603","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular response: update results of the STIM Study","volume":"118","author":"Mahon","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.leukres.2013.07.029_bib0230","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1080\/10428190902926973","article-title":"Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy","volume":"50","author":"Goh","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2013.07.029_bib0235","first-page":"2763","article-title":"Discontinuation of imatinib therapy in chronic myeloid leukemia patients with sustained complete molecular response4.5 (CMR4.5)","volume":"118","author":"Goh","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.leukres.2013.07.029_bib0240","first-page":"2121","article-title":"Imatinib discontinuation following a major molecular response: impact of interferon alpha and leukemia stem cell burden (The STOP Study)","volume":"112","author":"Koskenvesa","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.leukres.2013.07.029_bib0245","first-page":"3765","article-title":"Discontinuation of imatinib in patients with CML and sustained complete molecular response (CMR) for over 2 years in the Japanese population \u2013 an interim analysis of KEIO STIM Study","volume":"118","author":"Matsuki","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.leukres.2013.07.029_bib0250","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.07.029_bib0255","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.leukres.2008.10.024","article-title":"Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease","volume":"33","author":"Breccia","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2013.07.029_bib0260","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1080\/10428190600565057","article-title":"Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing","volume":"47","author":"Faber","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2013.07.029_bib0265","first-page":"3","article-title":"Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia","volume":"90","author":"Takahashi","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2013.07.029_bib0270","first-page":"916","article-title":"Discontinuation of second generation (2G) tyrosine kinase inhibitors (TKI) in chronic phase (CP)-chronic myeloid leukemia (CML) patients with stable undetectable BCR-ABL transcripts","volume":"120","author":"Rea","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.leukres.2013.07.029_bib0275","first-page":"605","article-title":"The natural history of RTQ-PCR levels after the achievement of complete molecular remission (CMR): implications for \u2018stopping\u2019 studies","volume":"118","author":"Milojkovic","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.leukres.2013.07.029_bib0280","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","article-title":"Dynamics of chronic myeloid leukaemia","volume":"435","author":"Michor","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2013.07.029_bib0285","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.1158\/1078-0432.CCR-11-0396","article-title":"BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment","volume":"17","author":"Stein","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2013.07.029_bib0290","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.07.029_bib0295","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment","volume":"118","author":"Chu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.07.029_bib0300","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","article-title":"Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells","volume":"109","author":"Jorgensen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.07.029_bib0305","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"(BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.07.029_bib0310","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.clml.2011.10.003","article-title":"Novel combination treatments targeting chronic myeloid leukemia stem cells","volume":"12","author":"Baghdadi","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.leukres.2013.07.029_bib0315","series-title":"The Chronic Myelogenous Leukemic Stem Cell: The Roadblock to Cure?","first-page":"275","author":"Bhatia","year":"2011"},{"key":"10.1016\/j.leukres.2013.07.029_bib0320","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/ng.389","article-title":"Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia","volume":"41","author":"Chen","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.leukres.2013.07.029_bib0325","first-page":"646","article-title":"Inhibition of Bcl-2\/Bcl-XL promotes apoptosis in blast crisis CML including quiescent primitive progenitor cells regardless of cellular responses to tyrosine kinase inhibitors","volume":"114","author":"Mak","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.leukres.2013.07.029_bib0330","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1182\/blood.V100.3.1068","article-title":"Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336","volume":"100","author":"Hoover","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.07.029_bib0335","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/sj.leu.2403785","article-title":"Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro","volume":"19","author":"Jorgensen","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.07.029_bib0340","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/cncr.22901","article-title":"Kantarjian H. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib","volume":"110","author":"Cortes","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2013.07.029_bib0345","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/cncr.23006","article-title":"Kantarjian H. Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure","volume":"110","author":"Cortes","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2013.07.029_bib0350","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature08734","article-title":"TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia","volume":"463","author":"Naka","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2013.07.029_bib0355","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood-2006-10-054098","article-title":"Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells","volume":"110","author":"Peng","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.07.029_bib0360","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07737","article-title":"Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia","volume":"458","author":"Zhao","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2013.07.029_bib0365","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","article-title":"Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate","volume":"17","author":"Zhang","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2013.07.029_bib0370","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2005-11-4639","article-title":"Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells","volume":"108","author":"Fiskus","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.07.029_bib0375","first-page":"1031","article-title":"Effective induction of apoptosis in chronic myeloid leukemia CD34+ cells by the histone deacetylase inhibitor LAQ824 in combination with imatinib","volume":"110","author":"Strauss","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.leukres.2013.07.029_bib0380","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature07815","article-title":"IFNalpha activates dormant haematopoietic stem cells in vivo","volume":"458","author":"Essers","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2013.07.029_bib0385","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","article-title":"Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia","volume":"28","author":"Burchert","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.07.029_bib0390","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3324\/haematol.2009.021246","article-title":"The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase","volume":"95","author":"Palandri","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2013.07.029_bib0395","first-page":"38","article-title":"A novel AHI-1-BCR-ABL-JAK2 interaction complex mediates cellular resistance to tyrosine kinase inhibitors in CML","volume":"114","author":"DeGeer","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.leukres.2013.07.029_bib0400","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/nature07016","article-title":"PML targeting eradicates quiescent leukaemia-initiating cells","volume":"453","author":"Ito","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2013.07.029_bib0405","first-page":"2168","article-title":"Wnt-pathway directed compound targets blast crisis and chronic phase CML leukemia stem progenitors","volume":"114","author":"Peterson","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613002725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613002725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:58:16Z","timestamp":1758934696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212613002725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":81,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0145212613002725"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2013.07.029","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Striving to achieve safe, permanent treatment discontinuation in chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2013.07.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}